Surgical Treatment for Advanced Oropharyngeal Cancer: A Narrative Review

Author:

Maniaci Antonino123,Hao Sheng-Po4,Cancemi Francesco1,Giardini Damiano56ORCID,Checcoli Emanuele56,Soprani Francesco56,Iannella Giannicola78ORCID,Vicini Claudio78,Cocuzza Salvatore1ORCID,La Mantia Ignazio1,Fakhry Nicolas23ORCID,De Vito Andrea56ORCID

Affiliation:

1. Department of Medical, Surgical and Advanced Technologies G.F.Ingrassia, ENT Section, University of Catania, 95123 Catania, Italy

2. Faculté des Sciences Médicales et Paramédicales, Aix-Marseille Université, 13005 Marseille, France

3. Pôle PROMO, Service ORL et Chirurgie Cervico-Faciale, Hôpital de la Conception, Assistance Publique des Hôpitaux de Marseille, 13005 Marseille, France

4. Department of Otolaryngology Head and Neck Surgery, Shin Kong Wu Ho-Su Memorial Hospital, School of Medicine, Fu-Jen University, Taipei 100, Taiwan

5. Department of Surgery, ENT Unit, “Santa Maria delle Croci” Hospital, 48121 Ravenna, Italy

6. “Umberto I” Hospital, Health Local Agency of Romagna, 48022 Lugo, Italy

7. Department of Surgery, ENT Unit, “Morgagni-Pierantoni” Hospital, 47121 Forlì, Italy

8. “Degli Infermi” Hospital, Health Local Agency of Romagna, 48018 Faenza, Italy

Abstract

Background and Objectives: to describe current scientific knowledge regarding the treatment options in advanced oropharyngeal cancer. The standard care for advanced oropharyngeal cancer (OPSCC) has been chemoradiotherapy, although surgical approaches followed by adjuvant treatment have been proposed. The best therapy for each patient should be decided by an interdisciplinary tumour-board. Different strategies should be considered for the specific patient’s treatment: surgery, chemotherapy and radiation therapy or combinations of them. The treatment choice is influenced by tumour variability and prognostic factors, but it also depends on cancer extension, extranodal extension, nervous invasion, human papilloma virus (HPV) presence, making the decisional algorithm not always clear. HPV-related OPSCC is strongly associated with a favourable overall survival (OS) and disease-free survival rate (DSS); by contrast, HPV-negative OPSCC often flags a worse prognosis. Consequently, the American Joint Committee on Cancer (AJCC) differentiates OPSCC treatment and prognosis based on HPV status. Methods: we carried out a review of current scientific literature to analyze the different indications and limitations of surgical treatment options in OPSCC stage III and IV. Conclusion: robotic surgery or open approaches with reconstructive flaps can be considered in advanced stages, resulting in the de-intensification of subsequent systemic therapy and fewer related side effects. Furthermore, in the event of the primary failure of systemic therapy or disease recurrence, the surgical approach constitutes an additional therapeutic option which lengthens patient survival functions.

Publisher

MDPI AG

Subject

General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3